(Q43737489)

English

Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jelić S

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Mitrović L

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Radosavljević D

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Elezar E

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Babović N

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Kovcin V

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Tomasević Z

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Kovacević S

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Gavrilović D

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Radulović S

10

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 October 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1-13

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer. Association of antitumor activity with initial tumor burden and treatment center

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin versus cisplatin in solid tumors: an analysis of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin and cisplatin: are they equivalent in efficacy in "optimal residual" advanced ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0169-5002(01)00239-2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43737489&oldid=2102936276"